Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intra-articular LNA043 for cartilage regeneration at knee donor sites after autologous chondrocyte implantation
2016-003418-28Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Traumatic cartilage degeneration, osteoarthritis (OA) and cartilage defect of knee comparing LNA043 with Placebo (2 arms). Primary endpoint: Cartilage glycosaminoglycan content and bi-layer collagen. Started Jan 2017; status: terminated.
02
Drugs
LNA043
03
Conditions
Traumatic cartilage degenerationosteoarthritis (OA)cartilage defect of knee
Beyond the preview
Go deeper on 2016-003418-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003418-28.